Mersana Therapeutics (NASDAQ:MRSN) Shares Up 3.7%
Mersana Therapeutics (NASDAQ:MRSN) Shares Up 3.7%
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating)'s share price shot up 3.7% on Friday . The stock traded as high as $6.66 and last traded at $6.66. 2,607 shares were traded during mid-day trading, a decline of 100% from the average session volume of 1,150,149 shares. The stock had previously closed at $6.42.
默萨纳治疗公司(纳斯达克代码:MRSN-GET Rating)股价周五飙升3.7%,盘中一度涨至6.66美元,最新报6.66美元。午盘成交量为2,607股,较1,150,149股的平均成交量下跌100%。此前该股收盘价为6.42美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Several brokerages recently weighed in on MRSN. Robert W. Baird boosted their price objective on shares of Mersana Therapeutics from $18.00 to $20.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 9th. Wedbush reaffirmed an "outperform" rating on shares of Mersana Therapeutics in a research report on Tuesday, August 9th. Finally, SVB Leerink upped their price target on shares of Mersana Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th.
几家券商最近加入了对MRSN的看法。罗伯特·W·贝尔德在8月9日星期二的一份研究报告中将Mersana治疗公司的股票目标价从18.00美元上调至20.00美元,并给予该股“跑赢大盘”的评级。韦德布什在8月9日星期二的一份研究报告中重申了对Mersana治疗公司股票的“跑赢大盘”评级。最后,SVB Leerink在8月9日星期二的一份研究报告中将Mersana Treeutics的股票目标价从13.00美元上调至14.00美元,并给予该公司“跑赢大盘”的评级。
Mersana Therapeutics Trading Up 5.9 %
Mersana治疗公司股价上涨5.9%
The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.18. The stock's 50-day simple moving average is $6.85 and its 200 day simple moving average is $5.03.
该公司的流动比率为3.32,速动比率为3.32,债务权益比率为0.18。该股的50日简单移动均线切入位为6.85美元,200日简单移动均线切入位为5.03美元。
Hedge Funds Weigh In On Mersana Therapeutics
对冲基金入股Mersana Treeutics
A number of institutional investors and hedge funds have recently made changes to their positions in MRSN. Victory Capital Management Inc. bought a new position in shares of Mersana Therapeutics during the 1st quarter worth about $36,000. Quantbot Technologies LP bought a new position in shares of Mersana Therapeutics during the 1st quarter worth about $37,000. Washington University bought a new position in shares of Mersana Therapeutics during the 2nd quarter worth about $43,000. Virtu Financial LLC bought a new position in shares of Mersana Therapeutics during the 1st quarter worth about $53,000. Finally, Point72 Hong Kong Ltd bought a new position in shares of Mersana Therapeutics during the 4th quarter worth about $57,000. Institutional investors own 95.12% of the company's stock.
一些机构投资者和对冲基金最近改变了他们在MRSN的头寸。胜利资本管理公司在第一季度购买了价值约3.6万美元的Mersana治疗公司的新股票头寸。Quantbot Technologies LP在第一季度购买了Mersana Treateutics的新头寸,价值约3.7万美元。华盛顿大学在第二季度购买了Mersana Treeutics的新头寸,价值约43,000美元。Virtu Financial LLC在第一季度购买了Mersana Treeutics的新头寸,价值约53,000美元。最后,Point72 Hong Kong Ltd在第四季度购买了Mersana Treeutics的新股票头寸,价值约57,000美元。机构投资者持有该公司95.12%的股票。
About Mersana Therapeutics
关于Mersana Treeutics
(Get Rating)
(获取评级)
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
Mersana治疗公司是一家临床阶段生物制药公司,为未得到满足需求的癌症患者开发抗体药物结合物(ADC)。它开发了XMT-1592,一种针对NaPi2b表达肿瘤细胞的Dolasynten ADC,正在进行治疗卵巢癌和NSCLC腺癌的I期临床试验。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Mersana Therapeutics (MRSN)
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- Let Paychex Stock Work Hard For You
- Thor Industries Hammers Out A Bottom
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- 免费获取StockNews.com关于Mersana治疗公司(MRSN)的研究报告
- 这是买入美光科技的难忘时刻
- 利润下降对CarMax价值主张的挑战
- 让Paychex股票为您努力工作
- 雷神工业走出谷底
- Keurig Dr Pepper与规模更大的竞争对手可口可乐(Coke&Pepsi)相比如何?
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Mersana治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Mersana Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。